Pharmaceuticals & Healthcare

Whether you’re from a drug company, industry association, consultancy, financial institution or government, we show you how and where business risks are most concentrated and highlight investment opportunities in the Pharmaceuticals & Healthcare market.

Daily Views

Actionable analysis across 185 global markets. Keep up-to-date with emerging trends, risks and opportunities affecting your organisation. From competitive intelligence to research and development pipelines, M&A and restructuring to regulatory developments, all analysis is available via the platform or as customisable daily email alerts.

Data & Forecasting

Compare and export data for 185 global markets. Our database contains 13 million lines of data, with 5 or 10 year forecasts across developed, emerging and frontier markets. Our proprietary databases provide further opportunities to identify growth and manage risk. Exclusive to Pharmaceuticals & Healthcare is the Burden of Disease Database, covering 123 different diseases and injuries across 187 countries, through to 2030.

The Pharmaceuticals & Healthcare team has a proven track record in monitoring industry developments and evolving business strategies and highlighting the most pertinent risks and opportunities in any global market.

Who buys and why?

Drug companies use our company performance data and market-level forecasts to evaluate growth strategies and rely on our reports to help identify new business opportunities and partners, especially in difficult to access countries or increasingly competitive environments.

Consultancies and sector specialists leverage our independence and expertise to further their views and advise clients and partners in the most informed way.

Government departments use our analysis to help shape policy and guide fully rounded decision making with a multi-sector and macro-strategy environment.

The current economic crisis in Greece will have implications for the pharmaceutical sector beyond the country's bor...The current economic crisis in Greece will have implications for the pharmaceutical sector beyond the country's borders. The system of international reference pricing wil...

New medicine pricing rules introduced by the Turkish government will enable drugmakers to raise their prices follow...New medicine pricing rules introduced by the Turkish government will enable drugmakers to raise their prices following years of price suppression. We expect these changes...

Federal presence within the pan-Canadian Pharmaceutical Alliance will lead to increased medicine procurement for ph...Federal presence within the pan-Canadian Pharmaceutical Alliance will lead to increased medicine procurement for pharmaceutical provision within the public sector. Despit...

Latest Blogs

The pharmaceutical sector is experiencing a period of consolidation and 'de-diversification' as increased competiti...The pharmaceutical sector is experiencing a period of consolidation and 'de-diversification' as increased competition and slower growth force companies to plan for the lo...

Since the first officially reported case in Guinea on March 21, the West Africa Ebola outbreak has spread to three ...Since the first officially reported case in Guinea on March 21, the West Africa Ebola outbreak has spread to three other countries (Sierra Leone, Liberia and, most recent...

Growth in the number of mobile phone users and the innovative application of communication technology to addre...Growth in the number of mobile phone users and the innovative application of communication technology to address health issues have the potential to transform the de...

Multinational pharmaceutical companies face significant declines in revenue when the patents on their best-selling ...Multinational pharmaceutical companies face significant declines in revenue when the patents on their best-selling drugs expire, allowing for the diffusion of cheaper cop...